Emerging Companies

Brenda Herschbach Jarrell and Jennifer Groves present an overview of the IP landscape in China, India, Brazil and Korea.

The 12th Annual BIO Investor Forum featured exciting panels, partnering meetings and more!

This backgrounder emphasizes the importance of strengthening the SBIR program to support bringing scientific innovation to the public.

The summary explains the criteria for investment companies, the process by which investment companies would apply and the manner in which the equity financing provided by the SBA could used.

The purpose of this survey was to examine technology transfer and licensing practices by biotechnology companies and determine its importance to the industry.

The Department of Energy's Assistant Secretary Cathy Zoi announced funding of $24 million for three research groups addressing key hurdles in commercialization of algae at the 2010 World Congress.

The Department of Energy's Assistant Secretary Cathy Zoi announced funding of $24 million for three research groups addressing key hurdles in commercialization of algae at the 2010 World Congress.

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

The “Valley of Death” — that sketchy period between when a startup settles on a technical approach and delivers a product to market — needn’t crush an early-stage biofuels business, say officers at three companies that are making that journey now.

There may be no summer lovin’ for biotechs. By most accounts, investors will remain tightfisted with their cash for some time, opening up their wallets for only the most promising investments. In a sign of how devastating the global economic crisis has become for the industry, more than a third of the 344 public biotechs had less than six months cash on hand by the end of March 2009, according to Burrill & Company statistics. And the situation is probably even bleaker among smaller, private companies.

The study provides first-of-its-kind data on the importance of university/industry research and development partnerships to the U.S. economy.

November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
February 12 2014
Bill would spur capital formation for small public companies
December 19 2013
More than 140 Companies Expected to Present Their Story to Top Public and Venture Capital Investors